Income statement, balance sheet and cash flow statement for the last 2 fiscal years, taken from the XBRL data Picard Medical, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2025
FY2025
Revenue
4.39
4.94
Cost of revenue
4.5
5.14
Gross profit
-0.11
-0.2
Research and development
3.38
3.05
Selling, general and administrative
10.2
10
Operating expenses
13.6
13.1
Operating income
-13.7
-13.3
Other non-operating income
-7.36
-13.7
Pre-tax income
-21.1
-27
Income tax
-0.02
0.04
Net income
-21.1
-27
EBITDA
-13.5
-13.1
EPS, basic
-2.99
-0.75
EPS, diluted
-2.99
-0.75
Shares, basic (weighted)
7.94
36.2
Shares, diluted (weighted)
7.94
36.2
Balance sheet
FY2025
FY2025
Cash and equivalents
0.1
7.45
Receivables
0.51
Inventory
8.12
7.3
Other current assets
0.96
1.22
Total current assets
9.79
20.7
Property, plant and equipment
0.23
0.18
Lease right-of-use assets
0.7
0.36
Goodwill
0.62
0.62
Intangible assets
0.6
0.51
Total assets
12.1
22.5
Accounts payable
5.29
2.08
Accrued liabilities
0.76
Total current liabilities
35.3
18.7
Lease liabilities
0.42
0.03
Total liabilities
35.8
18.8
Paid-in capital
5.56
80.4
Retained earnings
-49.8
-76.8
Other comprehensive income
0.28
0.23
Shareholders' equity
-44
3.79
Total equity
-44
3.79
Total liabilities and equity
12.1
22.5
Shares outstanding
7.94
1.47
Cash flow statement
FY2025
FY2025
Net income
-21.1
-27
Depreciation and amortization
0.23
0.16
Stock-based compensation
0.89
0.75
Deferred income tax
0
0
Change in receivables
0.12
-0.12
Change in inventory
-1.33
0.39
Change in payables
2.21
-3.21
Cash from operations
-11.9
-15.7
Cash from investing
0
Debt issued
9.7
Stock issued
0
15.2
Cash from financing
11.7
27.1
Net change in cash
-0.15
11.4
Interest paid
0
0.26
Income taxes paid
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $4.62 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
18.6%
Gross profit / revenue.
Operating margin
-248.4%
Operating income / revenue.
EBITDA margin
-245.6%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-444.7%
Pre-tax income / revenue.
Net margin
-444.8%
Net income / revenue.
Operating cash flow margin
-254.9%
Cash from operations / revenue.
Return on equity (ROE)
-1,631.0%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-305.4%
Net income / average total assets.
Return on invested capital (ROIC)
-735.9%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
75.8%
Research and development expense / revenue.
SG&A / revenue
191.2%
Selling, general and administrative expense / revenue.
Stock-based pay / revenue
31.4%
Stock-based compensation (from the cash flow statement) / revenue.
D&A / revenue
2.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
12.5%
Revenue vs the same period a year earlier. Only from a positive base.
Total assets growth, 1y
86.3%
Total assets vs the same period a year earlier. Only from a positive base.
Share count change, 1y
356.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.02x
Current assets / current liabilities.
Quick ratio
0.01x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.01x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$3.39
Revenue / diluted weighted shares.
Operating cash flow per share
-$8.64
Cash from operations / diluted weighted shares.
Book value per share
$0.83
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1.51x
Market cap / revenue.
P/B
5.53x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
14.9x
Market cap / tangible book value, when positive.
EV/Sales
1.50x
Enterprise value / revenue.
Earnings yield
-295.0%
Net income / market cap (the inverse of P/E).
What was Picard Medical, Inc.'s revenue in fiscal 2025?
Picard Medical, Inc. reported revenue of $4.9M for fiscal 2025, 12.5% higher than the year before.
Was Picard Medical, Inc. profitable in fiscal 2025?
No. It reported a net loss of $27.0M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.